Key red flags include pregnancy (no safety data, so contraindicated), active cancer (caution due to growth effects), autoimmune disorders, or organ failure
BPC-157 has shown interactions with vagal signaling in animal models, though the specifics of this interaction are still being characterized
Compounding BPC-157: A regulatory loophole In a statement, Health Canada said "BPC157 has not been authorized, its safety, efficacy, and quality have not been assessed and there is limited scientific evidence to support its use, including a lack of established human dosing protocols." In addition, the regulator says BPC-157 is not approved for use in any NHPs in any form, including oral and injectable, but it can still be compounded for topical use or oral administration as an NHP
At worst, it could contain contaminants
Step 1: Enter Vial Strength Input the total amount of BPC-157 in the vial, such as 5 mg or 10 mg